ARWR

Arrowhead Pharmaceuticals Inc (ARWR)

$70.09

Last Close (24-hour delay)

Today’s top pick

Profit since last BUY49.8%

Strong Buy

BUY since 13 days

• BUY Advisory
• SELL Advisory (Profit)
• SELL Advisory (Loss)

• Profit
• Loss
• Pass (Skip investing)

Stock price based on last close

*as per simulation
(see disclosures)

Upturn Star Rating

Outstanding Performance

These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.

Number of Analysts

15 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

Analysis of Past Performance

Type Stock

Historic Profit 53.53%

Avg. Invested days 25

Today’s Advisory Strong Buy

Upturn Star Rating

Upturn Advisory Performance 3.0

Stock Returns Performance 3.0

Profits based on simulation

Last Close 12/12/2025

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.